#Japan #AI Technology #Tokyo #University of Tokyo #Simplex Quantum

Exciting Advances in Heart Failure Monitoring

In a significant development for cardiovascular health, Simplex Quantum has partnered with the University of Tokyo Hospital to unveil a groundbreaking artificial intelligence (AI) technology focused on heart failure monitoring. This innovation, published in the International Journal of Cardiology, presents a new AI-driven system that accurately assesses heart failure severity using single-lead electrocardiogram (ECG) data from widely available devices, including popular wearables like the Apple Watch.

The Power of the HF-index

At the heart of this technology lies the HF-index, a novel metric that provides real-time monitoring of heart failure severity right from the comfort of home. This capability allows for timely clinical interventions, potentially decreasing the need for hospitalizations. The study demonstrated that this AI model, trained on ECG data from 9,518 individuals, achieved an impressive accuracy rate of 91.6% in classifying heart failure severity across various categories, including healthy, NYHA I–II (mild), and NYHA III–IV (moderate to severe) stages.

Key Findings of the Study

• - The AI model showcased Area Under Curve (AUC) values of up to 0.993, with sensitivity and specificity rates ranging from 89% to 97%.
• - The HF-index exhibited a strong correlation with plasma B-type Natriuretic Peptide (BNP) levels, a well-established biomarker in heart failure analysis (R = 0.74).

Dr. Katsuhito Fujiu, the project professor at the University of Tokyo and senior author of the study, emphasized the potential of the AI model in offering on-demand, non-invasive heart failure monitoring, even in the absence of symptoms. “It could drastically alter the landscape of patient care for individuals at risk of deteriorating heart failure by equipping both patients and clinicians with timely insights,” Dr. Fujiu remarked.

Ryu Saito, CEO of Simplex Quantum, expressed pride in the collaborative efforts with leading institutions to bring this innovative technology into routine practice. “These findings substantiate the clinical foundation of our solution and illustrate how AI can transform everyday devices into powerful medical tools,” said Saito.

A Solution to a Growing Problem

Heart failure impacts over 64 million people globally, making it one of the leading causes of hospital readmissions and escalating healthcare expenses. Traditional monitoring methods, which often involve invasive procedures or complex in-hospital diagnostics, can be prohibitively expensive and are frequently unavailable for many patients. The AI-driven solution introduced by Simplex Quantum offers a scalable alternative, allowing patients to utilize devices they are already familiar with to monitor their health effectively.

Details of the Study

• - Study Title: Heart Failure Monitoring with a Single-Lead Electrocardiogram at Home
• - Journal: International Journal of Cardiology
• - DOI: 10.1016/j.ijcard.2025.133203

Regulatory and Commercialization Track

The AI technology highlighted in this study is part of NIHA-HF, Simplex Quantum's investigational software platform designed for heart failure risk detection and monitoring. Regulatory submissions are in progress in both Japan and the United States, with product approvals anticipated in 2026.

About Simplex Quantum

Headquartered in Tokyo, Simplex Quantum specializes in medical AI solutions aimed at transforming cardiovascular diagnostics. With its flagship product, NIHA-HF, which leverages sophisticated neural network technologies to identify and monitor heart failure via ECG, the company seeks to bridge the gap between clinical-grade insights and user-friendly technology in everyday settings.

This revolutionary approach to heart health monitoring could mean a new era in patient care, offering hope to millions affected by heart failure – empowering them to take charge of their health like never before.